NEKTAR THERAPEUTICS NKTR
COM NEW · Common Stock · CUSIP 640268306 · ISIN US6402683063
American healthcare company
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersSan Francisco, CA
- Founded1990
- Websitenektar.com
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q2 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 1 |
| Q4 2022 | 1 |
| Q1 2023 | 1 |
| Q2 2023 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 0 | 0 |
| Q1 2023 | 0 | 0 |
| Q2 2023 | 0 | 1 |
Biggest buyers
| None |
Biggest sellers
| RAFFA WEALTH MANAGEMENT, LLC | Sold out | -33 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| FMR LLC 13G · institution +3.9 pts · filed 2026-05-06 | 15.0% |
| Two Seas Capital LP 13G · institution +0.7 pts · filed 2026-09-28 | 9.8% |
| BlackRock, Inc. 13G · institution +6.2 pts · filed 2026-07-29 | 7.8% |
| BIOTECHNOLOGY VALUE FUND L P 13G · passive investor -2.7 pts · filed 2026-08-14 | 7.1% |
| VANGUARD CAPITAL MANAGEMENT LLC 13G · institution new · filed 2026-07-31 | 5.2% |
Fell to 5% or below in the last year: VANGUARD GROUP INC (0.0%, 2026-03-27; now reported by VANGUARD CAPITAL MANAGEMENT LLC), SUSQUEHANNA SECURITIES, LLC (4.0%, 2026-02-13)
Insider purchases and sales in Q2 2023
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2021 | 0 | — | 0 | — | — |
| Q4 2021 | 0 | — | 6 | $1.4m | — |
| Q1 2022 | 0 | — | 6 | — | — |
| Q2 2022 | 0 | — | 6 | $352.4k | — |
| Q3 2022 | 0 | — | 8 | $596.4k | $6.8k |
| Q4 2022 | 0 | — | 4 | $254.4k | — |
| Q1 2023 | 0 | — | 4 | $146.0k | — |
| Q2 2023 | 0 | — | 4 | $44.2k | $17.1k |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2023-06-14 | WHITFIELD ROY A Director | Sold plan | $17.1k30.0k shares |
| 2023-05-16 | ROBIN HOWARD W President & CEO, director | Sold | $14.7k20.4k shares |
| 2023-05-16 | Zalevsky Jonathan Chief R&D Officer | Sold | $7.0k9.8k shares |
| 2023-05-16 | Wilson Mark Andrew Chief Legal Officer | Sold | $5.4k7.5k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q2 2023
| Manager | Shares | Change |
|---|